【論文摘要】Statin Centered Treatment

Jennifer Gaye Robinson

《海峽循環醫學雜誌》 1卷2S期 (2019/09) Pp. 190-190

https://doi.org/10.6907/SCJ.201909/SP_1(2).0156

摘要

Statins are the mainstay of atherosclerotic cardiovascular disease (ASCVD) prevention. Extensive data from over 28 trials with ＞185,000 participants has demonstrated that statins reduce ASCVD events in proportion to the magnitude of low density lipoprotein cholesterol (LDL-C) lowering. Each 1 mmol/L (39 mg/dL) reduction in LDL-C reduces the risk of major vascular events by 23%. High intensity statins are preferred in high risk populations, such as those with clinical ASCVD, genetic or familial hypercholesterolemia with LDL-C ＞4.9 mmol/L (190 mg/dL), diabetes with high risk characteristics, or primary prevention with ＞20% 10-year ASCVD risk.. Moderate intensity statins are preferred in lower risk primary prevention populations. Only after statin therapy has been established at the highest tolerated intensity should nonstatin therapy be considered. Symptoms during statin therapy are common, but are unlikely to be due to statin intolerance.